

1



Quarter three presentation October 16, 2009

Jan Erik Hedborg, CEO





Agenda

- Overview of ContextVision
- Operational highlights
- Market & product performance
- Financial results
- Strategic review






ContextVision

- Leading global independent image enhancement partner to medical imaging OEMs worldwide with an extensive list of over 50 customers including tier one vendors
- GOP® software offers the greatest accuracy available, enabling unprecedented diagnostic confidence, and can be fully customized to meet the needs of the end-users
- GOP software enables customers to rapidly deliver their products to market and provide next generation solution while focusing on their core business
- GOPiCE® US, volumetric image enhancement, has recently been launched as the first of our next generation solutions. Physicians have already identified that the product enables materially improved image clarity compared to 2D





Improved diagnostic value



Our products

Our customers are the manufacturer of medical imaging devices (OEM)



Magnetic Resonance Image: GOPView[™] MR Introduced 1987 (new update 2009)



Interventional Radiology: GOPView™ iRV Introduced 2008





Computed tomography: GOPView[™] CT Introduced 2006



Ultrasound: GOPView[™] US Introduced 2004 (new update 2008/ 2009)

CONTEXTVISION 差 💳

GOPiCE[™] US Introduced 2009



Q3 - operational highlights

- Growth in revenues in the previous quarter was not maintained due predominantly to weaker market conditions
- Extended 3 year supply agreement with Chinese ultrasound vendor
- Customer acceptance for two key projects (CT and interventional radiology), licenses revenues starts this quarter
- Technical and clinical evaluation of GOPiCE US by our two key customers is progressing well and we are targeting market introduction by our customers in the first half of 2010
- Japanese product approval received by one of our digital mammography customer





Market performance Q3 – Asia


- Decline in ultrasound volumes predominantly due to weak market conditions
- New customer leads in China and Korea, strong development amongst some Chinese manufacturers
- Well positioned for new GOPView iRV and GOPiCE US business in Japan & Korea





Market performance Q3 – Europe


- Sales lower than expeted within ultrasound and x-ray due to weak market conditions
- Extensive lead list including manufacturers in East Europe
- Well positioned for new **GOPView iRV** and **GOPiCE US** business





Market performance Q3 – America


- Decline in sales predominantly due to weak market conditions (30% less elective hospital procedures)
- Signs of order intake recovery in Q4 from our customers
- Well positioned for new **GOPView iRV** and **GOPiCE US** business



Sales by product



- Ultrasound and X-ray sales lower than expected predominantly due to weak global market conditions
- MR sales remains steady
- New product updates in XR and MR to be launched in Q4
- GOPView iRV & CT starts to generate license revenues in Q4 (will be reported in XR segment





Financial performance

Income statment

Income Stateme	ent (SEK 1000)					
	Q3 2009	Q3 2008	Nine months 2009	Nine months 2008	-	2008
Net sales	10 388	16 039	37 902	51 877	57 116	71 091
Other revenues	250	517	750	551	2 306	2 107
Total revenues	10 638	16 556	38 652	52 428	59 422	73 198
Goods for resale	-334	-366	-781	-1 140	-1 143	-1 502
Other external costs	-3 146	-3 178	-12 198	-11 260	-18 661	-17 723
Personnel costs	-6 418	-5 812	-22 793	-19 122	-30 392	-26 721
Depreciation assets	-666	-678	-1 966	-1 907	-2 648	-2 589
Operating results	74	6 522	914	18 999	6 578	24 663
Interest income	0	1 038	343	2 383	797	2 837
Interest costs and similar profit / loss items	-16	0	-17	-48	-32	-63
Results after financial items	58	7 560	1 240	21 334	7 343	27 437
Тах	-4	-2 105	-381	-5 947	-1 674	-7 240
Net results	54	5 455	859	15 387	5 669	20 197
Earnings per share after tax, SEK	0,08	0,67	0,10	1,89	1,38	2,49

- Revenue impacted predominantly by weaker global market conditions
- Personnel cost increased due to strategic recruitments 2008/2009
- Increased cost control (external costs)



Financial performance

Balance sheet

Consolidated Balance Sheet (SEK 1000)

	Q3 2009	Q3 2008	2008
Intangible fixed assets	13 017	9 789	11 311
Tangible assets	1 592	1 368	1 574
Financial assets	1 862	10 449	5 844
Inventories	707	537	429
Current receivables	18 530	23 400	16 498
Current investments	-	14 958	15 202
Cash and bank	13 821	19 504	16 201
Total assets	49 529	80 005	67 059
Equity	41 367	57 588	49 535
Provisions	1 162	1 829	947
Current liabilities	7 000	20 588	16 577
Total equity and liabilities	49 529	80 005	67 059

- Development work for GOPView iRV and GOPiCE US activated during 2008/2009
- Financial assets consist of shares in SharpView

 adjusted to market value
- Lower equity because of lower value financial assets and repurchase of own shares.
- Cash 13.8MSEK (end of Q3)



Financial performance Cash flow

			Nine months	Nine months
	Q3 2009	Q3 2008	2009	2008
Operation activities				
Result after financial items	58	7 560	1 240	21 334
Depreciation of assets	666	678	1 968	1 90
Jrealised gain/loss on current investments	-1 139	179	-280	-63
Changes in provisions	425	-	875	
ncome tax paid	-616	-821	-8 001	-6 46
Cash flow from operating activities	-606	7 596	-4 198	16 14
pefore change in working capital				
Change in working captial				
ncrease(-)/decrease(+) inventories	95	140	-278	17
ncrease(-)/decrease(+) current receivables	1 376	934	1 066	5 21
ncrease(+)/decrease(-) liabilities	-2 444	-441	-3 241	-5 54
Cash flow from operating activities	-1 579	8 229	-6 651	15 97
nvesting activities				
nvestments in intangible assets	-706	-1 029	-3 421	-4 04
nvestments in tangible assets	1	-36	-272	-17
nvestments in financial assets	-	-	-	-10 39
Short-term investments	-	-	15 202	13 81
Cash flow from investing activities	-705	-1 065	11 509	-80
inancing activities				
Cash dividend	-	-	-	-12 20
Repurchase of own stock	-	-	-7 239	
Sale of repurchased own stock	-	-	-	
Cash flow from financing activities	0	0	-7 239	-12 20
Cash flow for the period	-2 284	7 164	-2 381	2 96
Change of liquid assets				
iquid assets at beginning of period	16 105	12 340	16 201	16 53
iquid assets at period end	13 821	19 504	13 821	19 50

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _



Strategic review

- Board of Directors decided in August, as a consequence of the yearly strategic process, to pursue a merger or other strategic opportunities
- Nomura Code Securities, a leading European healthcare investment bank, has been appointed as advisor
- Target to be through the process as quickly as possibly, well aware of the importance of swift action in the interest of shareholders and other stakeholders
- There can be no assurance that a transaction will be entered into or completed as a result of this process



Strategic review

RATIONAL FOR A MERGER OR OTHER STRATEGIC OPPORTUNITIES

Optimize the value of the Company's world leading technology and products

- Combining ContextVision's core technology with other technology to create synergies for its customers
- Leverage customer relationships by enhancing existing ContextVision product offering
- Create economies of scale, and
- Build a stronger company brand towards end-users





ContextVision strengths & opportunities

- World leading technology and products
- Extensive customer base and market coverage
- Attractive market with strong underlying growth



Thank You!

